In the trial, published in the New England Journal of Medicine, angiodema symptoms were reduced by 95% among a small group of patients from the UK, New Zealand, and the Netherlands given a single infusion – targeted at cells in the liver – to reduce the KLKB1 gene’s ability to produce plasma prekallikrein.
Trending
- Ukraine-Russia peace talks: 'No progress' on territory nor future security guarantees
- Why scientists warn of privately funded geoengineering
- Gegijzeld door dwang, Désirée leefde jarenlang in angst: ‘Ik werd bang voor mijn eigen gedachten’
- Dad starts wargaming club for men's mental health
- Wealth manager Sidekick gets richer with £8m injection | Money News
- Social supermarket aims to provide affordable food
- Tiny dinosaur fossil could provide evolutionary clues: study
- China to ban hidden door handles seen on some electric cars | Money News
